

EPEX SPOT BELGIUM SA
- and -

GESTORE DEI MERCATI ENERGETICI S.P.A.

- and -

OMI POLO ESPAÑOL S.A.

- and -

EPEX SPOT SE

- and -

NORD POOL AS

-and-

OTE, a.s.

-and-

Towarowa Giełda Energii S.A.

-and-

OPCOM S.A.

-and-

Hellenic Energy Exchange S.A.

ADHERENCE AGREEMENT TO THE PCR COOPERATION AGREEMENT

 epexspot

 GME
Gestore
Mercati
Energetici

 EnEx
Energy Exchange Group
HELLENIC ENERGY EXCHANGE S.A.

 NORD
POOL

 omie

 opcom

 OTE

 TGE
POLISH POWER EXCHANGE

This adherence agreement (hereafter the “**Agreement**”) is entered into by and between:

1. **Nord Pool AS**, a company incorporated and existing under the laws of Norway, having its registered office at Vollsveien 17B, PO Box 121, 1325 Lysaker, registered with the commercial register in Norway n° 984 058 098, (hereafter “**Nord Pool**”);
2. **EPEX SPOT SE**, an European Company (Societas Europae) incorporated under the French Law, with registered office located at 5 boulevard Montmartre, 75002 Paris – France, and registered with the commercial register in Paris under the number 508 010 501, (hereafter “**EPEX**”);
3. **OMI– Polo Español S.A.**, a company incorporated and existing under the laws of Spain, having its registered office at Alfonso XI n° 6, 4ª planta, 28014 Madrid, Spain, and with the commercial register in Madrid under Section 8, Hoja: 506799, (hereafter “**OMIE**”);
4. **EPEX SPOT BELGIUM SA**, a limited liability company, incorporated and existing under the laws of Belgium, having its registered office at Boulevard de l’Impératrice 66, 1000 Brussels, Belgium, registered with the Registry of Enterprises (Brussels) under n° 0874978602, (hereafter “**EPEX Belgium**”);
5. **Gestore dei Mercati Energetici S.p.A.** is a company duly organised and existing under the Italian law, with registered office in Viale Maresciallo Pilsudski, 122-124, 00197, Rome, Italy, registered with the Companies' Register of Rome under number RM 953866, Italian tax code and VAT 06208031002, (hereafter “**GME**”);
6. **OTE, a.s.**, a company organised and existing under the laws of the Czech Republic, having its registered office at Sokolovská 192/79, 186 00 Praha 8, Czech Republic, and registered with Commercial Register in Prague Municipal Court in section B, file 7260, under number 26463318 and VAT n° CZ26463318, OTEs contract number: 7/13 (hereafter “**OTE**”);
7. **Towarowa Giełda Energii S.A.**, a company duly organized and existing under the laws of Poland, with the registered office at Książęca 4, 00-498 Warszawa, Poland, registered with National Court Register under number 0000030144 and VAT No PL5272266714, with the share capital paid in full in an amount of 14.500.000,00 PLN (hereafter “**TGE**”);
8. **Operatorul Pieței de Energie Electrică și de Gaze Naturale “OPCOM” S.A.**, a company duly organized and existing under the laws of Romania, with registered office in Bucharest, 16-18 Hristo Botev Bld., 3rd District, Romania, registered with Bucharest Trade Register Office under number J40/7542/2000, (hereafter “**OPCOM**”),

hereinafter individually also referred to as a “**PCR PX**” and collectively as the “**PCR PXs**”.

And

9. **HELLENIC ENERGY EXCHANGE S.A. (“HEEx S.A.”)**, a company duly organized and existing under the laws of Greece, with V.A.T. number 801001623, with registered office at 110, Athinon Avenue, 10442, Athens, Greece, registered in the commercial register at General Commercial Registry under number 146698601000, (hereafter called “**Adhering Party**”);

the PCR PXs and the Adhering Party hereafter individually also referred to as a “**Party**” and collectively as the “**Parties**”.

WHEREAS:

(1) On the 13th of June 2012, EPEX Belgium (formerly Belpex), EPEX, GME, OMIE and Nord Pool have signed the PCR Cooperation Agreement and the PCR Co-Ownership Agreement (the “**PCR Agreements**”) and, therefore, entered into a co-operation for the implementation of a single European day-ahead price coupling of power regions (hereafter the “PCR Cooperation”). The PCR Cooperation was preliminary launched, in 2009, by an initial collaboration between some of the PCR PXs regarding a first technical assessment of the coupling mechanism.

(2) On 28th February 2013 OTE signed an adherence agreement to the PCR Co-ownership Agreement and an adherence agreement to the PCR Cooperation Agreement and has formally joined PCR Cooperation as of the 1st of March 2013. Subsequently TGE and OPCOM joined PCR Cooperation adhering to the PCR Agreements on the 16th of October 2015 and respectively on the 30th of October 2015.

(3) Following the entering into force of COMMISSION REGULATION (EU) 2015/1222 of 24 July 2015 establishing a guideline on capacity allocation and congestion management (hereafter the “**CACM**”), the PCR PXs have started a negotiation in order to arrange the compliance of the PCR Agreements with CACM (hereafter the “**Negotiation**”). In particular, the Negotiation currently foresees the termination of the PCR Cooperation Agreement when the All Nemo Day Ahead Operational Agreement (hereafter the “**ANDOA**”) – to which all PCR PXs and the Adhering Party shall be party to - will enter into force.

(4) On the 6th of November 2012, Operator of Electricity Market S.A. (hereinafter “LAGIE”) has signed the Associate Member’s Confidentiality Declaration and the status of Associated Member was granted to the LAGIE by a decision of the Steering Committee dated 29.11.2012. LAGIE has subsequently extended the duration of Associate Member’s Confidentiality Declaration by signing the Amendment no. 1 to the PCR associate member confidentiality declaration on 11th of December 2013. The Confidentiality Declaration has been extended on 19th of April 2016 with a retroactive effect as from 6 November 2014 by signing the Addendum no. 2 to the PCR Confidentiality Declaration. The confidentiality declaration expired on 6th of November 2016 and was extended with retroactive effect as of 6th November until the 6th of November 2018 with Addendum no 3 signed on 15th February 2018 by LAGIE.

(5) LAGIE has expressed its interest in the participation in the PCR Cooperation. Following such first expression of interest, LAGIE, has formally requested to adhere to the PCR Cooperation by letter to the Steering Committee dated 15th of January 2018.

(6) On 22nd of February 2018 the PCR Steering Committee representing all PCR PXs has agreed to the adherence of the Adhering Party.

(7) On 18th of June 2018 due to the spin-off of the branch of LAGIE in accordance with the provisions of par. 1 of article 117B of Law 4001/2011, as amended by the article 96 of Law 4512/2018 and Hellenic Energy Exchange S.A. was established (distinctive title “HEnEx S.A.”).

(8) Adhering Party is the legal successor of LAGIE according to Article 117 E par. 1, 2 and 5 of Law 4001/2011 as amended by laws 4512/2018 and 4546/2018, since from the one hand all legal relationships pertaining to the branch of LAGIE are transferred to Adhering Party and on the other hand the NEMO designation is also transferred to Adhering Party according to the here above provisions.

(9) As a result of the above, all documents signed by LAGIE before 18th of June 2018 with regard to adherence to PCR Agreements are transferred to Adhering Party and are governed by the provisions to which LAGIE was subject at the time of the spin off.

(10) The Adhering Party fully acknowledges the content of the PCR Agreements as well as any other contract presently in force between the PCR PXs in the context of the PCR Cooperation as listed in Annex I (hereinafter the “**PCR Contracts**”). Therefore, the Adhering Party wishes to adhere to the PCR Cooperation Agreement subject to the terms of this Agreement.

NOW THEREFORE THE PARTIES AGREE AS FOLLOWS:

1. Adherence

1.1 The Adhering Party agrees to adhere to **the PCR Cooperation Agreement** and to the **PCR Contracts**, as listed exhaustively in Annex I to this Agreement and disclosed to Adhering Party, therefore accepting all the terms and conditions thereby provided, with no exclusion whatsoever. The PCR PXs hereby accept the adherence by the Adhering Party to the PCR Cooperation Agreement and to the PCR Contracts.

1.2 The Parties agree that the adherence to the PCR Cooperation Agreement and to the PCR Contracts by the Adhering Party will be retroactively effective as of the date of entering into force of the present Agreement (30th of June 2018), if the following conditions are duly fulfilled:

a) signature of the adherence agreement to the PCR Co-Ownership Agreement by the Adhering Party.

b) [REDACTED]

1.3 [REDACTED]

1.4 Should the payment of the Fee by the Adhering Party not be completed within the terms set forth under Annex I, the PCR PXs shall be entitled to:

- (i) immediately terminate this Agreement, and
- (ii) request the Adhering Party to pay a penalty equal to the amount due, pursuant to Article 1.3 of this Agreement, for the period between the entering into force of this

Agreement (i.e. 30th of June 2018) and the date of its termination. The Adhering Party shall pay the penalty, based on proven cost expense sheets produced by the PCR PXs consistently with art. 5.7 and Annex IX of the PCR Cooperation Agreement, within 10 working days from the receipt of the invoice related to such cost expense sheets.

- 1.5 For the purposes of art. 10.2.1. n. i) of PCR Cooperation Agreement, PCR PXs agree that the Adhering Party is entitled to disclose to its relevant NRA information regarding its costs and obligations deriving from its adherence to the PCR Cooperation Agreement.

2. Acknowledgements by the Parties

- 2.1 Upon signature of this Agreement, the Adhering Party declares to be fully aware of, all obligations of the PCR Cooperation Agreement and of the PCR Contracts presently in force.
- 2.2 In particular, the Adhering Party is fully acquainted with the content of Article 8.4 of PCR Cooperation Agreement and, as a result, acknowledges that it will bear an observer status within the PCR Cooperation for a limited period of three months starting from the efficacy of the Adhering Party's adherence to the PCR Cooperation Agreement pursuant to art 1.2 above (i.e. 30th of June 2018). Therefore, the Adhering Party shall accept, with no opposition whatsoever, each and all the decisions taken by the PCR PXs in the framework of the PCR Cooperation Agreement during this 3-months period.
- 2.3 PCR PXs declare that no relevant information for adherence of the Adhering Party to PCR Cooperation Agreement and to the PCR Contracts has been withheld. In particular, PCR PXs declare that the Adhering Party has received full access to the documentation concerning the ANDOA and that PCR PXs have not drafted at the time of the entering into force of this Agreement any further documentation concerning amendments to the PCR Cooperation Agreement provided that the Negotiation currently foresees the termination of the PCR Cooperation Agreement when the ANDOA will enter into force. The PCR PXs acknowledge that the Adhering Party is concluding the Agreement exclusively based on the information/documentation provided in the context of the ANDOA negotiations and by the PCR PX's with respect to the PCR Contracts.
- 2.4 Conversely, the Adhering Party declares that it is fully aware of the current status of the Negotiation between the PCR PXs in respect of the PCR Cooperation Agreement -which currently foresees its termination when the ANDOA will enter into force - as accessible through the documentation disclosed according to art. 2.3 above.
- 2.5 The Parties acknowledge and agree that in case any decision, also in respect of the ongoing negotiation cited in art 2.4 above, is taken during the Adhering Party's observer status which is proven to be, directly and exclusively, detrimental to the Adhering Party's interests only, the latter may claim the breach of art. 4.4 of the PCR Cooperation Agreement and, therefore, start the dispute resolution procedure set forth in art 17 thereof.

3. Entry into force and termination

- 3.1 This Agreement shall retroactively enter into force on the 30th of June 2018, provided that each Party, expressly derogating to Article 1325 of the Belgian Civil Code, has individually signed one original of the Agreement and sent a scanned copy of it to the other Parties and to the project manager office of the PCR Cooperation. Should the Parties not sign and send the scanned signatory page on the same day, the date of the receipt of the last scanned original of the Agreement shall trigger the entry into force. Subsequently, the Parties shall sign this Agreement as well in nine (9) original hard copies, one for each of the Parties.
- 3.2 This Agreement is entered into for the duration of the PCR Cooperation Agreement. For the avoidance of any doubt, should the PCR Cooperation Agreement be earlier terminated, this Agreement shall be terminated accordingly.
- 3.3 The parties are aware of the fact that OTE, a.s., irrespective of the applicable law of this Agreement, has a national legal obligation within the meaning of Section 2 (1) of Act No. 340/2015 Coll., *on special conditions for the entry into force of certain contracts, publishing and for the Registry of Contracts* according to which the entry into force of this Agreement is subject to prior publication of this Agreement and of a redacted version of the PCR Cooperation Agreement (with confidential parts blackened out) in the National Contract Registry.

4. Miscellaneous

- 4.1 No provision of this Agreement shall be interpreted adversely against a Party solely because that Party was responsible for drafting that particular provision.
- 4.2 Any change to this Agreement can only be validly agreed upon in writing, duly signed by the legal representatives of the Parties.
- 4.3 This Agreement shall in no event be considered a legal partnership or joint venture or other similar relation between the Parties. Each Party acknowledges that the Parties to this Agreement are independent entities and that it will not, except in accordance with this Agreement, represent itself as an agent or legal representative of the other Parties. Therefore, the Parties shall be responsible for their individual commitments only and do not bear any joint and several liabilities under this Agreement.
- 4.4 If one or more of the provisions of this Agreement is declared to be invalid, illegal or unenforceable in any respect under any applicable rule of law or public policy, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected and these provisions shall remain in full force and effect as long as the economic or legal substance of this Agreement is not affected in any material manner adverse to any Party. In such event, the Parties shall immediately and in good faith negotiate a legally valid replacement provision with the same economic effect.
- 4.5 The Parties agree that the working language for all notifications and for all matters relating to this Agreement shall be English, to the extent compatible with the applicable provisions of mandatory law, if any. Any term used in this Agreement with capital letter and not otherwise defined herein, shall have the same meaning ascribed to it in the PCR Cooperation Agreement.
- 4.6 The Annexes and the recitals to this Agreement form an integral part thereof and any reference to this Agreement shall include a reference to the Annexes and vice versa.

4.7 In case of contradiction or discrepancy between this Agreement and the Cooperation Agreement and/or any of their respective annexes the precedence shall be:

1. Main text of the PCR Cooperation Agreement;
2. Annexes to the PCR Cooperation Agreement;
3. Main body of this Agreement;
4. Annex 1 to this Agreement;




4.8 Parties may not assign or transfer this Agreement, partially or as a whole.





4.9 The present Agreement is governed by and construed with Belgian laws without regard to the conflict of laws principles of it.



4.10 Any dispute arising out of or in connection with this Agreement shall be settled in accordance with art 17 of the PCR Cooperation Agreement.

(The remainder of this page intentionally left blank)

In witness thereof, the Parties have caused their duly authorised representatives to execute the present Agreement in nine (9) original copies and each Party acknowledges having received its original copy.

For EPEX SPOT BELGIUM SA	
	
For GESTORE DEI MERCATI ENERGETICI S.P.A.	
	
For OMI POLO ESPAÑOL S.A.	
	

For EPEX SPOT SE 	
For NORD POOL AS 	
For OTE A.S. 	
For TGE S.A. 	

For OPCOM S.A. 	
For HEnEX S.A. 	

ANNEX I

List of PCR Contracts in force between the PCR PXs:

